Whitehawk Finds 100-Fold MUC16 Expression Advantage, Backs HWK-016 Phase 1
Whitehawk Therapeutics’ analysis shows MUC16 is expressed at 2- to over 100-fold higher levels than other ADC targets in high-grade serous ovarian carcinoma and 1.4- to 3.7-fold higher in aggressive endometrial subtypes. These findings underpin the clinical rationale for its MUC16-directed ADC HWK-016, now in Phase 1.
1. Real-World Expression Analysis
A large-scale RNA and protein analysis revealed MUC16 expression is 2- to over 100-fold higher than other ADC targets in high-grade serous ovarian carcinoma, and 1.4- to 3.7-fold higher in serous and endometrioid endometrial cancers. Expression remains stable across disease stages, metastatic status and platinum sensitivity, confirming durability.
2. Implications for ADC Development
These data validate MUC16 as a tumor-selective, high-density target and support HWK-016’s design to bind the membrane-bound, non-shed portion of MUC16. The ADC uses a cleavable linker and a novel topoisomerase I inhibitor payload to overcome the antigen sink effect.
3. HWK-016 Clinical Outlook
HWK-016 is currently in a Phase 1 trial for advanced ovarian and endometrial cancers, with initial clinical data expected in the first half of 2027. Positive early data could de-risk the program and accelerate development into earlier-line and combination settings.